

12 March 2020

Coronavirus: Impact minimised by PCK's digital business model

PainChek Ltd wishes to inform the market that at this stage there is no evidence that coronavirus is having an adverse impact on our sales cycle and ability to implement PainChek® in new residential aged care (RAC) customers, or in the use of PainChek® by existing customers.

In particular, PainChek®;

- is a software as a service technology that is deployed in the cloud and is not subject to territories or borders that can impact on supply to clients around the globe;
- is sold and supported by a comprehensive digital marketing program to maintain RAC customer reach, thereby minimising the need for sales and marketing personnel to have direct access to client premises;
- can be downloaded as an App remotely by all clients, typically from the Apple Store or Google Play Store and installed without the need for direct faced to face contact, thereby minimising the impact of any potential supplier entry restrictions imposed by RAC customers;
- is supported by readily available on-line training modules for use by our global clients enabling remote training and on-boarding;
- can be used on the readily available equipment of our customers (smartphones; iPad's and Tablets);
- can be used by care staff to assess pain on residents from up to 3 meters distance supporting existing RAC infection control strategies; and
- as an organisation born in the cloud, our business continuity plan is designed around enabling some or all of our workforce to productively work remotely, if required.

Management expect that the need for PainChek® in RAC will continue in a virus challenged world, as regular and reliable pain assessment remains a key duty of care for RAC operators, and the majority of residents in RAC suffer with pain (80%+) and live with dementia or cognitive impairment (60%+) irrespective of infectious virus symptoms.

PainChek Chief Executive Officer, Philip Daffas, said, *"We are taking a rational and considered approach to the coronavirus risk factor in our outlook. Our board meets regularly, and we will adapt and take decisive action as and when required."*

This release is authorised by Philip Daffas, Managing Director & CEO.

ENDS

For further information please
contact:

Ian Hobson
Company Secretary
Tel: +61 8 9388 8290

Philip Daffas
Managing Director
Tel: +61 406-537-235

About PainChek®

PainChek® Ltd is an Australian based company that develops pain assessment technologies.

PainChek® is a smart-phone based medical device using artificial intelligence to assess and score pain levels in real time and update medical records in the cloud. PainChek® records a short video of the person's face and analyses the images that indicate pain and records them.

Next, the caregiver uses PainChek® to record their observations of other pain related behaviours that complete the assessment. Finally, PainChek® calculates an overall pain score and stores the result allowing the caregiver to monitor the effect of medication and treatment over time.


PainChek® is being rolled out globally in two phases: first, PainChek® for adults who are unable to effectively verbalise their pain such as people with dementia, and second, PainChek® for Children who have not yet learnt to speak.

The PainChek® Shared Care Program is a PainChek® licensing model which enables a professional carer to share their resident or patient data securely with other healthcare professionals or designated homebased family carers for ongoing pain assessments or clinical data review.

To find out more, visit www.painchek.com



PainChek® artificial intelligence assesses facial micro-expressions that are indicative of the presence of pain.



PainChek® domains of pain assessment that calculates pain severity score.